2023年12月7日,美国凯斯西储大学医学院的研究人员在JAMA子刊JAMA Oncology上发表了一篇题为:GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes,With and Without Overweight/Obesity的研究论文。 该研究发...
Køber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785....
2023年12月7日,美国凯斯西储大学医学院的研究人员在JAMA子刊JAMA Oncology上发表了一篇题为:GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes,With and Without Overweight/Obesity 的研究论文。 该研究发现,无论是否肥胖,与其他抗糖尿病药物相比,GLP-1受体激动剂与...
appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. Diabetes Obes Metab. 2021;23(10):2344-53.
METHODS: This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 sites in 24 countries. Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either we...
资料5、Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study 资料6、Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With ...
《中华内分泌代谢杂志》、《中国糖尿病杂志》、《解放军医学杂志》、《药品评价》、Diabetes/Metabolism Research and Reviews等编委 参考文献: [1]Juan P.Frías,et al.Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes .August 5,2021.N Engl J Med 2021;385:503-515.DOI:10.1056...
[2] Ma, X. et al. Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells". Journal of Diabetes. 2014, 6, 394–402. [3] Gautier, J. F. et al. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes & Metabolism...
2019年,美国糖尿病协会(American Diabetes Association – ADA) (3) 和欧洲糖尿病协会(European Association for the Study of Diabetes,EASD) (4)推出了新的医治标准指南。指南建议不将胰岛素作为2型糖尿病的一线治疗,并将GLP-1受体激动剂在大多数情况下作为糖尿病的首选注射疗法。其依据概括为如下三方面: ...
标签:GLP-1;β细胞;2型糖尿病糖尿病(diabetesmellitus,DM)是一组以慢性血糖水平增高为特征的代谢疾病群。其中,2型糖尿病(type2diabetesmellitus,T2DM)占本病群体的95%,糖尿病人数正在在全球范围内日益剧增。据世界卫生组织统计,预计到21世纪30年代世界糖尿病患病将达到3.34亿。糖尿病并发症多,且有较高的致残致死...